SEATTLE, March 15, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the presentation of data from the VENUS trial by Dr. Bert Lopansri of Intermountain Medical Center at the 36th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium.
The presentation describes the diagnostic variability observed between physicians when assessing patients with systemic inflammation for likelihood of infection at admission, at discharge and over patient stay. The study indicates that in approximately one in three patients, no confident admission diagnosis is possible, and that even with comprehensive follow-up information, a similar proportion of patients cannot be confidently classified as having an infection or not. Also, it was found that in roughly one third of patients, the admission diagnosis was changed when downstream information became available during the hospital stay. These results also suggest that it is especially difficult to confirm a diagnosis in patients with lower respiratory tract infections, such as pneumonia.
"This research supports the need for an objective diagnostic tool for sepsis as indicated by discordance in the ability of physicians to reach consensus for a diagnosis in suspected sepsis patients," said Dr. Roslyn Brandon, President and CEO of Immunexpress. "This is especially apparent in patients with lower respiratory tract infections in which the current workflow and diagnostics fail in the context of early detection of sepsis. Our solution, SeptiCyte™ LAB, offers clinicians a diagnostic tool for suspected sepsis patients."
Sepsis is a life-threatening condition that arises when the body's response to infection damages its own tissues and organs. Confirming a sepsis diagnosis today aims to identify the pathogen only and therefore has serious limitations in respect of speed and sensitivity. The Immunexpress SeptiCyte™ LAB solution evaluates the host immune response to aid clinicians in quickly and accurately diagnosing sepsis in patients suspected of sepsis.
About Immunexpress
Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients suspected of sepsis. Immunexpress's SeptiCyte™ technology quantifies directly from whole blood specific molecular markers from the patient's own immune system – the "host response." Detecting the host's septic immune response has the potential to identify sepsis earlier and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen because it is independent of whether or not the pathogen is in the blood sample. Immunexpress's pipeline includes monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer instrumentation. For more information visit www.Immunexpress.com.
Follow Immunexpress on Twitter at twitter.com/Immunexpress and LinkedIn at www.linkedin.com/company/immunexpress-inc.
Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4262
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
SOURCE Immunexpress, Inc.